Get the Stockscreener App
1.82
2.25%
0.04
After Hours:
1.80
-0.02
-1.10%
Chemomab Therapeutics Ltd Adr stock is traded at $1.82, with a volume of 37,413.
It is up +2.25% in the last 24 hours and up +26.39% over the past month.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
See More
Previous Close:
$1.78
Open:
$1.79
24h Volume:
37,413
Relative Volume:
0.20
Market Cap:
$34.32M
Revenue:
-
Net Income/Loss:
$-33.08M
P/E Ratio:
-0.619
EPS:
-2.94
Net Cash Flow:
$-25.68M
1W Performance:
+10.30%
1M Performance:
+26.39%
6M Performance:
+91.58%
1Y Performance:
+225.17%
1-Day Range:
$1.75
$1.86
1-Week Range:
$1.57
$1.86
52-Week Range:
$0.42
$2.55
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
Name
Chemomab Therapeutics Ltd Adr
Sector
Industry
Phone
972-77-331-0156
Address
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Compare CMMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMMB
Chemomab Therapeutics Ltd Adr
|
1.82 | 34.32M | 0 | -33.08M | -25.68M | -2.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-24 | Initiated | Maxim Group | Buy |
| May-06-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-19-23 | Resumed | ROTH MKM | Buy |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Latest News
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis - GlobeNewswire Inc.
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Investing.com
Chemomab reports progress in PSC treatment trial - Investing.com
Roth MKM Initiates Coverage of Chemomab Therapeutics LtdADR (CMMB) with Buy Recommendation - MSN
The Chemomab Therapeutics Ltd ADR (CMMB) had a good session last reading, didn’t it? - US Post News
Financial Health Check: Examining Chemomab Therapeutics Ltd ADR (CMMB)’s Key Ratios - The Dwinnex
Chemomab Therapeutics Ltd ADR (CMMB) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Ratios Uncovered: Breaking Down Chemomab Therapeutics Ltd ADR (CMMB)’s Trailing Twelve Months Metrics - The Dwinnex
Is Chemomab Therapeutics Ltd ADR (CMMB) a good investment opportunity? - US Post News
CMMB stock touches 52-week high at $2.07 amid market fluctuations - Investing.com
Chemomab Therapeutics Ltd ADR (CMMB) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Are Chemomab Therapeutics Ltd ADR (CMMB) shares a good deal now? - US Post News
CMMB stock touches 52-week high at $1.58 amid market fluctuations - Investing.com India
Chemomab Therapeutics Ltd ADR (CMMB) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Market Analysts see American Express Co. [AXP] gaining to $265. Time to buy? - The DBT News
Chemomab Therapeutics Ltd ADR [CMMB] moved down -16.20: Why It’s Important - The DBT News
Chemomab regains Nasdaq compliance with bid price rule - Investing.com
Public Service Enterprise Group Inc. [PEG] Revenue clocked in at $9.72 billion, up 21.41% YTD: What’s Next? - The DBT News
Cerevel Therapeutics Holdings Inc [CERE] Is Currently 2.37 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Ardelyx Inc [ARDX] moved down -2.31: Why It’s Important - The DBT News
CMMB’s 2023 Market Dance: Up 107.84% – Time to Invest? - The InvestChronicle
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise - Benzinga
Chemomab secures $10 million in PIPE financing - Investing.com India
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy? - Yahoo News Malaysia
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know - MSN
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - Investing.com India
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update - Investing.com India
LGVN Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast - CNN
Why Copart, Inc. (CPRT) is a Top Momentum Stock for the Long-Term - Zacks Investment Research
Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why - Zacks Investment Research
Chemomab Stock: Leading Anti-CCL24 mAb For Fibrotic Diseases (NASDAQ:CMMB) - Seeking Alpha
Chemomab And AGC Biologics Partner To Manufacture CM-101 For Phase II/III - Contract Pharma
Chemomab Therapeutics (CMMB) Stock Price, News & Analysis - MarketBeat
Chemomab Therapeutics (NASDAQ:CMMB) Stock Quotes, Forecast and News Summary - Benzinga
The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal - Yahoo Finance
Chemomab Therapeutics Ltd Adr Stock (CMMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):